135 related articles for article (PubMed ID: 25896003)
1. Methods for assembling B-cell lymphoma specific and internalizing aptamer-siRNA nanoparticles via the sticky bridge.
Zhou J; Rossi JJ; Shum KT
Methods Mol Biol; 2015; 1297():169-85. PubMed ID: 25896003
[TBL] [Abstract][Full Text] [Related]
2. Dual functional BAFF receptor aptamers inhibit ligand-induced proliferation and deliver siRNAs to NHL cells.
Zhou J; Tiemann K; Chomchan P; Alluin J; Swiderski P; Burnett J; Zhang X; Forman S; Chen R; Rossi J
Nucleic Acids Res; 2013 Apr; 41(7):4266-83. PubMed ID: 23470998
[TBL] [Abstract][Full Text] [Related]
3. Dual functional RNA nanoparticles containing phi29 motor pRNA and anti-gp120 aptamer for cell-type specific delivery and HIV-1 inhibition.
Zhou J; Shu Y; Guo P; Smith DD; Rossi JJ
Methods; 2011 Jun; 54(2):284-94. PubMed ID: 21256218
[TBL] [Abstract][Full Text] [Related]
4. Aptamer-targeted RNAi for HIV-1 therapy.
Zhou J; Rossi JJ
Methods Mol Biol; 2011; 721():355-71. PubMed ID: 21431697
[TBL] [Abstract][Full Text] [Related]
5. Novel dual inhibitory function aptamer-siRNA delivery system for HIV-1 therapy.
Zhou J; Li H; Li S; Zaia J; Rossi JJ
Mol Ther; 2008 Aug; 16(8):1481-9. PubMed ID: 18461053
[TBL] [Abstract][Full Text] [Related]
6. Anti-Mucin1 Aptamer-Conjugated Chitosan Nanoparticles for Targeted Co-Delivery of Docetaxel and IGF-1R siRNA to SKBR3 Metastatic Breast Cancer Cells.
Jafari R; Majidi Zolbanin N; Majidi J; Atyabi F; Yousefi M; Jadidi-Niaragh F; Aghebati-Maleki L; Shanehbandi D; Soltani Zangbar MS; Rafatpanah H
Iran Biomed J; 2019 Jan; 23(1):21-33. PubMed ID: 30041514
[TBL] [Abstract][Full Text] [Related]
7. Functional assays for specific targeting and delivery of RNA nanoparticles to brain tumor.
Lee TJ; Haque F; Vieweger M; Yoo JY; Kaur B; Guo P; Croce CM
Methods Mol Biol; 2015; 1297():137-52. PubMed ID: 25896001
[TBL] [Abstract][Full Text] [Related]
8. Aptamer-functionalized hybrid nanoparticle for the treatment of breast cancer.
Powell D; Chandra S; Dodson K; Shaheen F; Wiltz K; Ireland S; Syed M; Dash S; Wiese T; Mandal T; Kundu A
Eur J Pharm Biopharm; 2017 May; 114():108-118. PubMed ID: 28131717
[TBL] [Abstract][Full Text] [Related]
9. Development of cell-type specific anti-HIV gp120 aptamers for siRNA delivery.
Zhou J; Li H; Zhang J; Piotr S; Rossi J
J Vis Exp; 2011 Jun; (52):. PubMed ID: 21730942
[TBL] [Abstract][Full Text] [Related]
10. CTLA4 aptamer delivers STAT3 siRNA to tumor-associated and malignant T cells.
Herrmann A; Priceman SJ; Swiderski P; Kujawski M; Xin H; Cherryholmes GA; Zhang W; Zhang C; Lahtz C; Kowolik C; Forman SJ; Kortylewski M; Yu H
J Clin Invest; 2014 Jul; 124(7):2977-87. PubMed ID: 24892807
[TBL] [Abstract][Full Text] [Related]
11. Stick-Based Methods for Aptamer-Mediated siRNA Targeted Delivery.
Catuogno S; Esposito CL; Giangrande PH
Methods Mol Biol; 2021; 2282():31-42. PubMed ID: 33928568
[TBL] [Abstract][Full Text] [Related]
12. siRNA-aptamer chimeras on nanoparticles: preserving targeting functionality for effective gene silencing.
Bagalkot V; Gao X
ACS Nano; 2011 Oct; 5(10):8131-9. PubMed ID: 21936502
[TBL] [Abstract][Full Text] [Related]
13. Aptamer-conjugated DNA icosahedral nanoparticles as a carrier of doxorubicin for cancer therapy.
Chang M; Yang CS; Huang DM
ACS Nano; 2011 Aug; 5(8):6156-63. PubMed ID: 21732610
[TBL] [Abstract][Full Text] [Related]
14. A peptide-targeted delivery system with pH-sensitive amphiphilic cell membrane disruption for efficient receptor-mediated siRNA delivery.
Wang XL; Xu R; Lu ZR
J Control Release; 2009 Mar; 134(3):207-13. PubMed ID: 19135104
[TBL] [Abstract][Full Text] [Related]
15. Targeting Cancer Cells Using LNA-Modified Aptamer-siRNA Chimeras.
Subramanian N; Kanwar JR; Kanwar RK; Krishnakumar S
Nucleic Acid Ther; 2015 Dec; 25(6):317-22. PubMed ID: 26334953
[TBL] [Abstract][Full Text] [Related]
16. Functional in vivo delivery of multiplexed anti-HIV-1 siRNAs via a chemically synthesized aptamer with a sticky bridge.
Zhou J; Neff CP; Swiderski P; Li H; Smith DD; Aboellail T; Remling-Mulder L; Akkina R; Rossi JJ
Mol Ther; 2013 Jan; 21(1):192-200. PubMed ID: 23164935
[TBL] [Abstract][Full Text] [Related]
17. Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras.
McNamara JO; Andrechek ER; Wang Y; Viles KD; Rempel RE; Gilboa E; Sullenger BA; Giangrande PH
Nat Biotechnol; 2006 Aug; 24(8):1005-15. PubMed ID: 16823371
[TBL] [Abstract][Full Text] [Related]
18. Mechanistic insights into LDL nanoparticle-mediated siRNA delivery.
Jin H; Lovell JF; Chen J; Lin Q; Ding L; Ng KK; Pandey RK; Manoharan M; Zhang Z; Zheng G
Bioconjug Chem; 2012 Jan; 23(1):33-41. PubMed ID: 22142191
[TBL] [Abstract][Full Text] [Related]
19. Cell-specific induction of apoptosis by rationally designed bivalent aptamer-siRNA transcripts silencing eukaryotic elongation factor 2.
Wullner U; Neef I; Eller A; Kleines M; Tur MK; Barth S
Curr Cancer Drug Targets; 2008 Nov; 8(7):554-65. PubMed ID: 18991566
[TBL] [Abstract][Full Text] [Related]
20. Smart ligand: aptamer-mediated targeted delivery of chemotherapeutic drugs and siRNA for cancer therapy.
Li X; Zhao Q; Qiu L
J Control Release; 2013 Oct; 171(2):152-62. PubMed ID: 23777885
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
